AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
39 hedge funds and large institutions have $6.66M invested in AEON Biopharma Inc in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
+$278K |
| 2 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$219K |
| 3 |
LA
Linden Advisors
New York
|
+$152K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$152K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$150K |
Top Sellers
AEON.WS Hedge Fund Activity: Q2 2021 in Review
39 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q2 2021, worth a combined $6.66M.
Buyers outnumbered sellers: 39 funds opened new AEON.WS positions and 0 closed out — a net gain of 39 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Davidson Kempner Capital Management, opening a new position worth an estimated $278K.
- 39 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $6.66M of AEON Biopharma Inc stock for Q2 2021.
- 39 funds opened new AEON Biopharma Inc positions in Q2 2021 and 0 closed out, a net change of +39 holders.
- The largest AEON Biopharma Inc buyer in Q2 2021 was Davidson Kempner Capital Management, an estimated $278K added.
Based on aggregated 13F filings for Q2 2021.